フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Neovasc Inc. Announces Receipt of Final Approval to Graduate to the TSX PR Newswire VANCOUVER, June 20, 2014 NASDAQ: NVCN TSX VENTURE: NVC...
Neovasc Inc. reports results of Annual General Meeting of Shareholders PR Newswire VANCOUVER, June 19, 2014 NASDAQ: NVCN TSX VENTURE: NVC...
Neovasc earns a spot in 2014 PROFIT 500 List PR Newswire VANCOUVER, June 12, 2014 NASDAQ: NVCN TSX VENTURE: NVC VANCOUVER, June 12, 2014...
Neovasc Inc. provides initial comments on lawsuit PR Newswire VANCOUVER, June 6, 2014 NASDAQ: NVCN TSX VENTURE: NVC VANCOUVER, June 6, 2014...
Neovasc Inc. reports financial results for first quarter 2014 PR Newswire VANCOUVER, May 22, 2014 NASDAQ: NVCN TSX VENTURE: NVC --Reports...
Positive First-In-Human Experience With Neovasc's Tiara™ Transcatheter Mitral Valve Presented at EuroPCR 2014 PR Newswire PARIS, France...
Neovasc Inc. to begin trading on the NASDAQ Capital Market PR Newswire VANCOUVER, May 16, 2014 NASDAQ: NVCN TSX VENTURE: NVC VANCOUVER, May 16...
Neovasc receives first US patent for its novel Tiara(TM) transcatheter mitral valve replacement technology PR Newswire VANCOUVER, Nov. 13, 2013...
Neovasc Reducer™ Achieves Primary Endpoint in COSIRA Trial, Significantly Improving Functional Capabilities in Patients with Refractory...
Neovasc Inc. Announces Publication of Positive Tiara™ Preclinical Data in the Journal JACC: Cardiovascular Interventions PR...
Neovasc Inc. announces upcoming presentations at TCT 2013 scientific symposium PR Newswire VANCOUVER, Oct. 24, 2013 Neovasc's Tiara™...
Neovasc Inc. reports financial results for second quarter of 2013 PR Newswire VANCOUVER, Aug. 15, 2013 --Year-over-Year Revenues Increased 71...
Neovasc's COSIRA clinical trial protocol selected for publication in peer-reviewed journal PR Newswire VANCOUVER, Feb. 28, 2013 -Trial...
Neovasc Inc. reports financial results for third quarter of 2012 #ReleaseContent TABLE { BORDER-COLLAPSE: collapse } TR.cnwUnderlinedCell...
Neovasc Inc. Finalizes US $4.6 Million Agreement Giving Lemaitre Vascular Rights to In-House Manufacture of Xenosure® Surgical...
Support
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
サインアップして広告なしのエクスペリエンスを体験してください
今すぐ試してください
広告を残す